Phase II trial of carboplatin plus cetuximab for the treatment of stage IIIB/IV non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Bradford, D. S.
Socinski, M. A.
LaRocca, R. V.
Hensing, T. A.
Bordoni, R. E.
机构：
[1] Highlands Oncol Grp, Fayetteville, AR USA
[2] Univ N Carolina, Chapel Hill, NC 27515 USA
[3] Kentuckiana Canc Inst, Louisville, KY USA
[4] Evanston Northwestern Healthcare, Evanston, IL USA
[5] Georgia Canc Specialists, Marietta, GA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
18005
引用
下载
收藏
页数：2
相关论文
共 50 条
  • [41] Phase II trial of docetaxel and carboplatin in the treatment of advanced non-small cell lung cancer
    Schutte, W
    Bork, I
    Wollschlager, B
    Schadlich, S
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 1076 - 1076
  • [42] Preliminary results of a randomized phase II trial of pemetrexed (P) plus carboplatin (Cb) ± enzastaurin (ENZ) versus docetaxel (D) plus Cb as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer (NSCLC)
    Kocs, D. M.
    Raju, R. N.
    Socinski, M. A.
    Stinchcombe, T. E.
    Rousey, S. R.
    Barrera, D.
    Wang, Y.
    Bromund, J.
    Treat, J.
    Obasaju, C. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [43] Elderly subgroup analysis of a randomized phase 3 trial of gemcitabine (G) in combination with carboplatin (Cb) or paclitaxel (P) compared to paclitaxel plus carboplatin in advanced (stage IIIB, IV) non-small cell lung cancer (NSCLC)
    Ansari, R. H.
    Gonin, R.
    Socinski, M.
    Edelman, M.
    Catalano, R.
    Marinucci, D.
    Comis, R.
    Obasaju, C.
    Treat, J. A.
    Belani, C. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [44] A phase II, monotherapy study of YM155 inpatients with advanced stage IIIB or IV non-small cell lung cancer (NSCLC)
    Giaccone, G.
    Zatloukal, P.
    Jaromir, R.
    Mousil, J.
    Kuta, M.
    van Klaveren, R. J.
    Chaudhary, S.
    Gunther, A.
    Kazei, D.
    Verbeek, F.
    ANNALS OF ONCOLOGY, 2007, 18 : 40 - 40
  • [45] Phase II study of taxol combined with ifosfamide and carboplatin in the treatment of stage IIIb-IV non-small-cell lung cancer
    Zaniboni, A
    Ardizzoni, A
    De Marinis, F
    Portalone, L
    Boni, C
    Meriggi, F
    Cafferata, MA
    Ariganello, O
    Torri, V
    Neumaier, CE
    Rosso, R
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2003, 26 (01): : 84 - 88
  • [46] A phase I/II trial of weekly docetaxel and gefitinib in elderly patients with stage IIIB/IV non-small cell lung cancer
    Stinchcombe, Thomas E.
    Buzkova, Petra
    Choksi, Janak
    Taylor, Mark
    Bakri, Kamal
    Gillenwater, Heidi
    Tynan, Maureen
    Mears, Andrea
    Jones, Paul E.
    Socinski, Mark A.
    LUNG CANCER, 2006, 52 (03) : 305 - 311
  • [47] Phase II study of cetuximab in combination with carboplatin and docetaxel for patients with advanced/metastatic non-small cell lung cancer (NSCLC)
    Belani, C. P.
    Ramalingam, S.
    Schreeder, M.
    Steis, R.
    Guidice, R.
    Marshland, T.
    Butler, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [48] Phase II trial of sequenced bevacizumab and erlotinib with bevacizumab and chemotherapy for 1st line stage IIIB or IV non-small cell lung cancer (NSCLC)
    Cohen, E.
    Govindan, R.
    Kozloff, M.
    Mauer, A.
    Hoffman, P.
    Karrison, T.
    Stein, J.
    Szeto, L.
    Salgia, R.
    Vokes, E.
    EJC SUPPLEMENTS, 2006, 4 (12): : 42 - 43
  • [49] Phase I-II trial of carboplatin (CBDCA) an vinorelbine (VNR) in stage IV non-small cell lung cancer (NSCLC).: A pilot study of Spanish Lung Cancer Group
    Massutí, B
    Barneto, I
    Meana, JA
    Herrero, J
    Picó, C
    Aranda, E
    García, MA
    de la Gándara, I
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S260 - S261
  • [50] A phase I study of paclitaxel in combination with etoposide in patients with stage IIIB/IV non-small cell lung cancer (NSCLC)
    Ukena, D
    Berg, M
    Leutz, M
    Zell, L
    Schlimmer, P
    Sybrecht, GW
    LUNG CANCER, 1998, 19 (01) : 31 - 36
12345